Navigation Links
For Treatment of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabThera's Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
Date:8/30/2010

used in preference to the brand if the price differences are favorable and efficacy/safety are the same as the brand.

The report is based on a survey of 251 hematologist-oncologists from Germany (52), France (50), Italy (49), Spain (50) and the United Kingdom (50) and interviews with 15 European payers from Germany (3), France (3), Italy (3), Spain (3) and the United Kingdom (3).

WebinarMedia members are welcome to attend our upcoming webinar based on this report entitled European Clinician and Payer Perspectives on the Dominance of Roche's MabThera in NHL and CLL – Will Emerging Monoclonal Antibodies Be Able to Compete? This online presentation will be held on September 22, 2010 at 10 a.m. U.S. Eastern Time. For more information, please contact Christopher Comfort at ccomfort@dresources.com.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Tianyin Pharmaceutical Co., ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today announced that the Company achieved the Public ... Practice (GMP) certificate of TPI,s Qionglai Facility (QLF) ... The public notice period is a significant procedure ...
(Date:12/22/2014)... NxStage Medical, Inc. (NASDAQ: NXTM ... announced today that the U.S. Food and Drug ... perform hemodialysis overnight while the patient is at ... System One is the first and only hemodialysis ... Home nocturnal hemodialysis is an ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held ... Moraviec has been appointed Interim Chief Executive Officer of ... Moraviec succeeds Ken Berger .  "The Board of ... in leading ConvaTec over the past three years," said ... of Directors.  "We are confident that the company is ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... Oct. 18, 2011 Octapharma USA ... over the next few months, including AABB,s 64th Annual ... 25 and National Hemophilia Foundation,s (NHF) 63rd Annual Meeting ... In December, Octapharma USA will also participate in the ...
... Oct. 18, 2011 For thousands of nurses, lab technicians, ... of shopping for the latest in scrub fashions that are ... on the success of the 10 original stores that launched ... to open in Tampa, Orlando and Miami FL; Rochester and ...
Cached Medicine Technology:Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH 2Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH 3Octapharma USA to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH 4An RX for Busy Healthcare Professionals 2An RX for Busy Healthcare Professionals 3
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive ... and marketing of a series of induction heating equipment. ... series of induction brazing equipments . , According ... brazing refers to the joining of two or ... The manager says that there are fundamental differences in ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... When head lice hits a home or school, parents and ... of it while keeping it from taking over the house ... solution right in their neighborhood: Lice Troopers . Expanding ... spectrum head lice screening and treatment services to families and ... Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , The ...
(Date:12/25/2014)... early stage breast cancer patients who undergo chemotherapy and/or ... eventually develop leukemia as a result of their treatment, ... a review of more than 20,000 breast cancer cases ... the risk for developing treatment-related leukemia, though low, is ... frequency of bone marrow cancers such as leukemia is ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... , , , HATBORO, Pa., ... a leading technology provider of enterprise mobility solutions for the healthcare ... panel discussion as part of Mobile Monday Mid-Atlantic, Monday September 21, ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090618/NE35135LOGO ) ...
... , , , ... NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic ... financing with institutional and other accredited investors, including members of ... half of the offering. Gross proceeds of approximately $2.9 million ...
... HLTH Corporation (Nasdaq: HLTH ) today announced that ... segment to affiliates of Aurora Capital Group, a Los Angeles based ... the fourth quarter and is subject to customary closing conditions, including ... Act. , , The purchase price of ...
... Sept. 18 NBTY, Inc. (NYSE: NTY ) ( ... today announced that it will web cast presentations by Harvey Kamil, President ... , , Mr. Kamil,s presentation at the ... 2009 will be web cast at 4:30 PM Eastern Time that day. ...
... , , CLEVELAND, Sept. ... 45-minute seminar that highlights the critical need for long-term care insurance ... available. It will be held at multiple times in 4 Ohio ... , , *(PHOTO 72dpi: Send2Press.com/mediaboom/09-0910-3in4ltc_72dpi.jpg) ...
... , , , ... www.maxhealthcare.in ) and Perot Systems Corporation (NYSE: PER ... which Perot Systems will provide IT outsourcing (ITO) and electronic health records ... in the Indian healthcare industry as well as the company,s first India-based ...
Cached Medicine News:Health News:InfoLogix to Present 'Mobile in the Enterprise: Keeping up with User Demand While Containing Costs' at Mobile Monday Panel in Philadelphia 2Health News:InfoLogix to Present 'Mobile in the Enterprise: Keeping up with User Demand While Containing Costs' at Mobile Monday Panel in Philadelphia 3Health News:NewCardio Completes $2.9 Million Private Placement 2Health News:NewCardio Completes $2.9 Million Private Placement 3Health News:NewCardio Completes $2.9 Million Private Placement 4Health News:HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for $142 Million 2Health News:HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for $142 Million 3Health News:NBTY to Web Cast Presentations at UBS Global Life Sciences Conference and Canaccord Adams Healthy Living Conference 2Health News:NBTY to Web Cast Presentations at UBS Global Life Sciences Conference and Canaccord Adams Healthy Living Conference 3Health News:Long Term Care Seminars in Dayton, Cleveland, Cincinnati, and Columbus -- Free to Public 2Health News:Long Term Care Seminars in Dayton, Cleveland, Cincinnati, and Columbus -- Free to Public 3Health News:Max Healthcare of India Selects Perot Systems for Over Rs. 90 Crores ($18 Million) 10-year IT Services and Electronic Health Records Implementation 2Health News:Max Healthcare of India Selects Perot Systems for Over Rs. 90 Crores ($18 Million) 10-year IT Services and Electronic Health Records Implementation 3Health News:Max Healthcare of India Selects Perot Systems for Over Rs. 90 Crores ($18 Million) 10-year IT Services and Electronic Health Records Implementation 4Health News:Max Healthcare of India Selects Perot Systems for Over Rs. 90 Crores ($18 Million) 10-year IT Services and Electronic Health Records Implementation 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: